Logo

ACQUISITIONS

Acquisitions as a driving force of long-term and profitable growth

Acquisitions are an important part of AddLife’s growth strategy and we have a well‑established and structured process to identify, acquire, integrate and develop companies. The process leading up to a new acquisition can span several years. We strive for a long‑term and close dialogue with entrepreneurs based on our fundamental values and decentralized management model. Ahead of an acquisition, a shared vision and plan for the company’s future is established.

STRATEGY IDENTIFICATION EVALUATION TRANSACTION INTEGRATION

Acquisition criteria

  • Net sales <SEK 50 million
  • EBITA margin >12 percent
  • Entrepreneur‑driven
  • Operating in prioritised segments

Cumulative acquisition statistics since 2016

  • Number of acquisitions 36
  • Added annual net sales SEK 5,900 million
  •  Employees 1,800

Identification

AddLife continuously looks for well‑established and profitable European Life Science companies to acquire, that want to continue developing as part of the AddLife family. New companies can add new market niches, presence in new geographic markets and/or complement the existing product and service offering. Preferably, the companies are small or medium‑sized with good profitability, have a robust business model and a corporate culture in line with AddLife’s, as well as a strong position in selected segments and geographies. Continued commitment from management and key individuals is also an important criterion.

AddLife has a continuous inflow of new interesting and attractive acquisition candidates, primarily through AddLife’s network of subsidiaries as well as through the Group’s own structured search process. Initial contact with potential acquisition candidates also sometimes takes place via external corporate advisers and brokers. The ambition is to enter into a close and exclusive dialogue with the company’s owners at an early stage of the process.

Evaluation

When a potential acquisition candidate has been identified and both parties agree to continue the dialogue, the process enters an evaluation phase. Potential acquisitions are evaluated based on a number of criteria, such as market position and brand, product offering, customers, well‑established supplier relationships, knowledge and technology content, competitors, ESG parameters, financial position, and the leadership and continued commitment of key individuals. The way in which the business is conducted – with commitment and responsibility – is crucial to creating long‑term sustainable growth and profitability, and is therefore of great importance in the evaluation.

Transaction

In the transaction phase, AddLife and the acquisition candidate agree on a value that makes the deal value‑creating for both parties. We most often use an acquisition model with clear shared targets and an earn‑out structure, whereby part of the purchase consideration is paid if the company meets its profitability targets after the acquisition. It is also important that the acquired company’s key suppliers and partners consent to the acquisition. The agreement results in a transfer contract and, once signed, the transaction is communicated in a press release.

Adobestock 560959402

Limited integration

Within AddLife’s decentralised business model, each company is responsible for its own strategy and earnings and retains its brand and identity. Operations are conducted independently and with considerable freedom with responsibility. Integration is therefore relatively limited and mainly consists of implementing AddLife’s model for financial management and AddLife’s corporate culture through training in AddLife’s core values, Code of Conduct, financial targets and sustainability. In this way, the acquired companies maintain their entrepreneurial spirit and their customer and business focus, and are not burdened by administrative processes and integration projects. With this limited integration, the focus on customers and business is maintained, and acquisition processes can also be handled more efficiently.

Continuous development

In line with AddLife’s ambition to continuously develop, evaluation and improvement are a natural part of our acquisition process. After the process has been completed, regardless of whether the acquisition has been carried out or not, all parties involved are invited to discuss strengths and potential areas for improvement. For completed acquisitions, representatives from the acquisition candidate are also included. The evaluation also includes thorough financial follow‑up to ensure that the acquired companies develop in line with expectations.

Active and value‑creating ownership

By becoming part of AddLife, the acquired company gains a long‑term owner with industry expertise that supports management through active and committed ownership. Financial stability, resources and tools are provided that make it easier and more efficient to develop the business. AddLife also supports the companies by appointing a Board of Directors with expertise adapted to the companies’ size, segment and business situation.

2016 2017 2018 2019 2020 2021 COVID-19 PANDEMIC 2022 2023 2024 2025 MEDIPLAST GROUP FUNKSJONS- UTSTYR BIOLIN SCIENTIFIC KORPINEN AddLife HEPRO LABTECH MEDTECH BIOMEDICA LAB-VENT BERGMANLABORA BIONORDIKA HOLM & HALBY IMMUNO DIAGNOSTIC LABROBOT TRIOLAB SVAN CARE BIOMEDICA ITALIA HC21 EUROCLONE BIO- CONNECT ROPOX DACH MEDICAL ZAFE FISCHER MEDICAL ADDVISION MBA EDGE MEDICAL OPITEK BONSAILAB EMMAT MEDICAL O’FLYNN MEDICAL JK LAB NORDIC BIOCAT Subsidiaries of AddLife since start on Nasdaq AddLife standalone acquisitions
Adobestock 167778573

HC21 – The caring company

Healthcare 21 was founded twenty‑two years ago with the ambition of offering healthcare products and services tailored for the 21st century. From the very start, its motto has been “the caring company”, and culture has always been a central part of HC21. With passionate and committed employees, HC21 delivers high‑quality products and services within 15 different therapy areas in the Irish market. The company shares AddLife’s culture and has delivered strong results in line with our financial targets and key performance indicators.

Watch the movie here!

 

Acquisitions during the year

In 2025 AddLife completed three acquisitions. In total, the acquisitions are expected to add annual net sales of approximately SEK 140 million and include 42 employees. The acquisitions strengthen the Group’s position in prioritised growth segments and geographies and are in line with AddLife’s acquisition strategy.


Edge Medical

Edge Medical is a leading UK distributor within orthopaedic surgery, spinal surgery and neurology, with operations in England and Ireland. The company has a strong market position and a high margin profile. Edge Medical will be part of the Medtech business area.

  • Acquisition date: 1 April 2025
  • Net sales: approximately SEK 90 million
  • Number of employees: 20


Pharmacold

Pharmacold is a Danish company specialised in cooling technology and service for the pharmaceutical and healthcare sectors. The company offers unique, customer‑specific solutions that ensure correct temperature control and operational reliability in critical environments. Pharmacold will be part of the Labtech business area.

  • Acquisition date: 1 December 2025
  • Net sales: approximately SEK 38 million
  • Number of employees: 20


Opitek

Opitek is a Danish company that manufactures specialised solutions for patient positioning. The company has a niche product portfolio with a strong medical technology profile and complements AddLife’s existing offering in surgery. Opitek will be part of the Medtech business area.

  • Acquisition date: 1 December 2025
  • Net sales: approximately SEK 12 million
  • Number of employees: 2

Loading...